January 4, 2012: Profectus BioSciences, Inc. announces first Human Volunteer Immunized in Clinical Trial of Profectus BioSciences’ Vesicular Stomatitis Virus-vectored HIV-1 Vaccine. Learn More >

December 19, 2011: Profectus BioSciences, Inc., The International AIDS Vaccine Initiative (IAVI) and Ichor Medical Systems announce today the start of a multicenter Phase I trial in Africa. Learn More >

December 12, 2011: Profectus BioSciences, Inc. receives $5.4M grant to develop a monocolonal antibody against infection by nipah/hendra viruses. Learn More >

November 15, 2011: Profectus BioSciences, Inc. awarded follow-on grant from Path Malaria Vaccine Initiative(MVI). Learn More >

September 21, 2011: Profectus BioSciences, Inc. In-Licenses Portfolio of Patents to Support Vesicular Stomatitis Virus-vectored Vaccine for Ebola and Marburg Viruses. Learn More >

May 25, 2011: Profectus BioSciences, Inc. announces Initiation of Phase I Clinical Trial to EvaluateSafety and Immunogenicity of a Vesicular Stomatitis Virus-vectored HIV-1Vaccine. Learn More >

May 25, 2011: Profectus BioSciences, Inc. announced today that the AIDS Clinical Trials Group (ACTG) has immunized the first subject in a U.S. phase 1 clinical trial of Profectus’ multi-antigen HIV plasmid DNA (MAG-pDNA). Learn More >

January 5, 2011: Profectus BioSciences, Inc. annouces Initiation of Clinical Trial of IL-12 Enhances Therapeutic HIV DNA Vaccine Delivered Using Electroporation. Learn More >

December 14, 2010: Profectus BioSciences, Inc. GENEVAX™ IL-12 Adjuvant Significantly Improves pDNA Vaccine Performance in Phase I Human Trial.Learn More >

October 6, 2010: Profectus BioSciences, Inc. Receives $6.25M in National Institute of Allergy and Infectious Disease Grants and Contracts. Learn More >

October 4, 2010: Profectus BioSciences, Inc. Receives $4.4M in Grants to Develop an HIV Prophylactic Vaccine. Learn More >

March 2, 2010: Ichor Medical Systems and Profectus Biosciences Enter into an Agreement for Use of TriGridTM Electroporation Device to Develop Multiple DNA Vaccines. Learn More >

January 7, 2010: Profectus BioSciences, Inc. to present at key investor conference in January 2010. Learn More >

August 25, 2009: Profectus BioSciences, Inc. enters into research collaboration agreement with The Path Malaria Vaccine Initiative(MVI). Learn More >

August 17, 2009: Profectus BioSciences, Inc. to present data at Immunotherapeutics & Vaccine summit. Learn More >

July 22, 2009: Profectus BioSciences, Inc. secures $5M in Series C Venture Funding. Learn More >

July 20, 2009: Empire State Development Attracts Profectus BioSciences to NY.Learn More >

June 8, 2009: Profectus BioSciences, Inc., receives 2009 Best of Baltimore Award. Learn More >

May 14, 2009: Profectus BioSciences, Inc. to present at 2009 BIO International Conference in Atlanta. Learn More >

April 24, 2009: Profectus BioSciences, Inc. to present new data at 12th Annual Conference on Vaccine Research. Learn More >

March 30, 2009: Profectus BioSciences, Inc. to present at upcoming investor meetings. Learn More >

December 8, 2008: Profectus BioSciences, Inc. Awarded $21.6 Million in NIH Contracts to Develop a HIV Preventative and a HIV Therapeutic Vaccine. Learn More >

November 10, 2008: Profectus executes an Assignment and License Agreement with Wyeth for vaccines against HIV, HCV, HPV, and HSV. Learn More >

September 17, 2008: Profectus BioSciences, Inc. Industry Pioneer Joins, to support Innovation in Therapeutic and Preventative Vaccines. Learn More >

January 24, 2008: Profectus BioSciences, Inc. Names Shawn Patrick O’Brien CEO. Learn More >

July 19, 2007: Profectus BioSciences, Inc. Receives NIH Grant to Enhance Future Anti-HIV Therapies. Learn More >

June 19, 2007: Profectus BioSciences, Inc. Announces NIH Grant. Learn More >

June 15, 2007: Profectus BioSciences, Inc. Announces Additional $3 Million Private Placement of Convertible Notes and Warrants. Learn More >

March 14, 2007: Four firms and research center garner Greater Baltimore Committee's 2007 Baltimore region bioscience awards. Learn More >

2006: 2006 Maryland Incubator Company of the Year Awards: 2006 Technology Transfer Company of the Year. Learn More >

May 30,2006: Profectus BioSciences, Inc. Announces Additional $3 Million Private Placement of Equity Securities
Learn More >

February 1, 2005: UMBI’s Institute of Human Virology Spins Off New Biotechnology Company, Profectus BioSciences, Inc. to Develop Products to Help Combat Spread of AIDS
Learn More>